Oscotec Valuation

Q: What is the Fair Price of A039200 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A039200 (₩53000) is trading below our estimate of [[future cash flow value]] (₩132496.53)

Is A039200 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of A039200 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: A039200 (₩53000) is trading below our estimate of future cash flow value (₩132496.53)

Significantly Below Future Cash Flow Value: A039200 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039200?

Key metric: As A039200 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A039200. This is calculated by dividing A039200's market cap by their current earnings.
What is A039200's PE Ratio?
PE Ratio	38.7x
Earnings	₩52.34b
Market Cap	₩2.03t

A039200 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.4x
Enterprise Value/EBITDA	36.1x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does A039200's PE Ratio compare to its peers?

The above table shows the PE ratio for A039200 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
A069620 Daewoong Pharmaceutical	8.9x	-5.52%	₩1.7t
A237690 ST PharmLtd	53.8x	23.79%	₩3.0t
A086450 DongKook Pharmaceutical	17.4x	15.00%	₩1.2t
A185750 Chong Kun Dang Pharmaceutical	15.1x	5.70%	₩1.2t
A039200 Oscotec	38.7x	34.55%	₩2.0t

Price-To-Earnings vs Peers: A039200 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the peer average (23.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does A039200's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
A006620 DongKoo Bio & Pharma	2.9x	n/a	US$98.60m
A007370 Jin Yang Pharmaceutical	2.8x	n/a	US$42.60m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A039200 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the KR Pharmaceuticals industry average (15.2x).

Price to Earnings Ratio vs Fair Ratio

What is A039200's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039200 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	38.7x
Fair PE Ratio	32.6x

Price-To-Earnings vs Fair Ratio: A039200 is expensive based on its Price-To-Earnings Ratio (38.7x) compared to the estimated Fair Price-To-Earnings Ratio (32.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystPriceTarget

Community Contributor

₩75k

Fair Value

29.3% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/20 04:19
End of Day Share Price	2026/04/20 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oscotec Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Haesoon Kwon	Eugene Investment & Securities Co Ltd.
Sangsoo Kim	Goldman Sachs
Wan Ku	iM Securities